MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Lannett Company ROCE Ratio 2011-2025 | LCI
Annual ROCE Ratio Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70.21 | 863.64 | 6.46 | 11.59 | 12.9 | 13.44 | 13.5 | 48.74 | 29.78 | 13.93 | 5.86 | -1.04 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 863.64 | -1.04 | 90.75 |
Quarterly ROCE Ratio Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.52 | 34.36 | 83.59 | 96.1 | 362.52 | 350.95 | 129.42 | 112.2 | -236.79 | -239.09 | -66.36 | -63.46 | 13.07 | 16.03 | 22.1 | -85.46 | -84.36 | -196.86 | -200.14 | -88.4 | -86.13 | 30.75 | 29.2 | 18.29 | 16.08 | 5.07 | 4.2 | 18.3 | 18.65 | 33.41 | 45.44 | 51.63 | 67.68 | 75.15 | 68.36 | 44.58 | 41.72 | 14.9 | 8.12 | 18.67 | 3.16 | 14.74 | 11.22 | 9.37 | 5.61 | 3.66 | 1.36 | 0.47 | 1.37 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 362.52 | -239.09 | 11.75 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-24.04 | $ 1.21 | 1.68 % | $ 130 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-190.63 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
-10.43 | $ 2.67 | 0.19 % | $ 1.39 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
-249.5 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
34.66 | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-23.09 | $ 4.35 | -3.12 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
-13.16 | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
-184.26 | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-39.6 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.61 | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-76.25 | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
-111.87 | $ 12.29 | -1.09 % | $ 629 M | USA |
 |
Athenex
ATNX
|
1076.15 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | $ 21.57 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-623.16 | $ 6.66 | -3.55 % | $ 413 M | USA |
 |
Harrow Health
HROW
|
0.61 | $ 50.7 | 1.22 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
-59.23 | $ 1.27 | -1.32 % | $ 22.2 M |  China |
 |
OrganiGram Holdings
OGI
|
-35.84 | $ 1.7 | -5.31 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-29.88 | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.49 | $ 5.19 | -1.71 % | $ 683 M | USA |
 |
Bausch Health Companies
BHC
|
-94.23 | $ 7.16 | -0.56 % | $ 2.61 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 3.66 | 0.83 % | $ 4.54 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-8.06 | $ 4.01 | -2.55 % | $ 56.4 M | USA |
 |
Rockwell Medical
RMTI
|
-31.33 | $ 0.8 | -7.01 % | $ 18.7 M | USA |
 |
Pacira BioSciences
PCRX
|
-9.43 | $ 26.17 | -1.3 % | $ 1.21 B | USA |
 |
Sundial Growers
SNDL
|
-68.48 | $ 1.71 | -1.16 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
5.46 | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | USA |
 |
Veru
VERU
|
-114.23 | $ 2.22 | -7.71 % | $ 299 M | USA |
 |
Perrigo Company plc
PRGO
|
1.31 | $ 13.94 | 0.87 % | $ 1.92 B | USA |
 |
ProPhase Labs
PRPH
|
32.97 | $ 0.45 | -14.17 % | $ 7.13 M | USA |
 |
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
-235.96 | $ 1.43 | -15.88 % | $ 6.17 M | USA |
 |
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-121.49 | $ 4.43 | -1.77 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
26.27 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-176.47 | $ 9.56 | -3.82 % | $ 679 M | USA |
 |
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-81.9 | $ 5.63 | -3.68 % | $ 230 M | USA |
 |
SCYNEXIS
SCYX
|
99.6 | $ 0.63 | 6.75 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-41.31 | $ 9.32 | -2.87 % | $ 5.76 B | Canada |
 |
TherapeuticsMD
TXMD
|
-29.1 | $ 1.68 | -3.43 % | $ 17.5 M | USA |